Cowpea mosaic virus (CPMV) has been developed as a promising nanoplatform technology
for cancer immunotherapy; when applied as in situ vaccine, CPMV exhibits potent, systemic …

Cowpea mosaic virus (CPMV) is currently in the development pipeline for multiple
biomedical applications, including cancer immunotherapy. In particular the application of …

Cowpea mosaic virus (CPMV) is a nucleoprotein nanoparticle that functions as a highly
potent immunomodulator when administered intratumorally and is used as an in situ …

Plant virus nanoparticles can be used as drug carriers, imaging reagents, vaccine carriers,
and immune adjuvants in the formulation of intratumoral in situ cancer vaccines. One …

Cowpea mosaic virus (CPMV) is a plant virus that has been developed for multiple
biomedical and nanotechnology applications, including immunotherapy. Two key platforms …

Cowpea mosaic virus (CPMV) has demonstrated superior immune stimulation and efficacy
as an intratumoral immunotherapy, providing a strong argument for its clinical translation …

In situ cancer vaccination that uses immune stimulating agents is revolutionizing the way
that cancer is treated. In this realm, viruses and noninfectious virus-like particles have …

Cancer immunotherapy approaches have emerged as novel treatment regimens against
cancer. A particularly interesting avenue is the concept of in situ vaccination, where …

Viral immunotherapies are being recognized in cancer treatment, with several currently
approved or undergoing clinical testing. While contemporary approaches have focused on …

In situ vaccination for cancer immunotherapy uses intratumoral administration of small
molecules, proteins, nanoparticles, or viruses that activate pathogen recognition receptors …